ABSTRACT OBJECTIVES This study sought to assess the incidence and clinical impact of stent fracture (SF) after the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES).
. Stent fracture (SF) after DES implantation has recently become an important concern because of its potential association with ISR, TLR, and ST (4). The incidence of SF in the clinical setting has been reported to be 0.84% to 8.4% in first-generation DES (5, 6) . In the newer-generation DES, we previously reported that SF after cobalt chromium everolimus-eluting stent (CoCr-EES) implantation occurs in 2.9% of lesions and is associated with a higher rate of major adverse cardiac events, driven by higher rates of TLR and ST (7) . More recently, we also reported SF after the Nobori biolimus-eluting stent (BES) (Terumo, Tokyo, Japan) implantation occurs in 4.1% of lesions, and the incidence of TLR is higher in the SF lesion compared with the non-SF lesion (8) . Therefore, SF is still an unresolved, clinically relevant issue even in the newergeneration DES era.
The platinum-chromium everolimus-eluting stent (PtCr-EES) is a newer-generation DES that uses the same drug and polymer as CoCr-EES but combines them with a novel metal alloy and stent design intended to improve deliverability, conformability, radiopacity, radial strength, and fracture resistance Kuramitsu et al. Table 1 Table 1 . There were no significant differences between the 2 groups except for left ventricular ejection fraction.
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ANGIOGRAPHIC AND PROCEDURAL CHARACTERISTICS
AND RESULTS. The angiographic and procedural characteristics and results of both groups are shown in Table 2 . Compared with the non-SF group, the prevalence of the right coronary artery location, ISR at baseline, tortuosity, and hinge motion were significantly higher in the SF group. Index stent types that caused ISR at baseline included as follows:
33 BMS, 27 BES, 12 sirolimus-eluting stents (SES), were type 3a, and 5 (27.8%) were type 3b (Figure 2A) . Figure 2B show the classification of angiographic SF and the relationship between angiographic SF classification and TLR. Figure 3 and Online Figure 1 show representative cases with type 2, 3a, and 3b SFs.
In the present study, 5 (27.8%) SFs were detected by using IVUS or OCT and performing a careful review of the angiogram. All SFs detected by using IVUS or OCT were complete fractures. The SFs were located in the mid-portion (50%), overlap portion (22.2%), proximal portion (16.7%), and distal portion (11.1%).
The predictors of SF after PtCr-EES implantation on multivariable logistic analysis are shown in Table 3 
DISCUSSION
The main findings of the present study are: 1) the incidence of SF after PtCr-EES implantation was 1.7% 
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A U G U S T 1 7 , 2 0 1 5 : 1 1 8 0 -8 of lesions; 2) SF appeared to be associated with higher rates of TLR; and 3) lesions with ISR at baseline, hinge motion, and total stent length were identified as predictors of SF.
The incidence of SF in the clinical setting has been reported to be 0.84% to 8.4% in first-generation DES (5, 6) . Of the newer-generation DES, we previously reported that SF after CoCr-EES and BES implantation was observed in 2.9% and 4.1% of lesions, respectively, and was associated with a higher rate of major cardiac events, mainly driven by higher TLR or ST (7, 8) . The PROMUS Element is a newer-generation DES with a novel metal alloy and stent design intended to improve deliverability and conformability, increase radial strength and radiopacity, and reduce recoil compared with previous DES. Bench testing indicates the PtCr-EES may be less likely than other DES to develop strut fracture over time (16) . However, there are currently no data regarding the incidence and clinical impact of SF after PtCr-EES implantation.
In the present study, despite a high prevalence of lesions with hinge motion or tortuosity, the incidence of SF after PtCr-EES implantation was 1.7% of lesions, which was lower than that after CoCr-EES and BES implantation (7, 8) . Therefore, PtCr-EES may be more resistant to fractures as compared with CoCr-EES and BES.
An optimal stent design incorporates a balance of desirable characteristics; however, an improvement in one feature may adversely affect other attributes of the stent platform. PtCr-EES is reportedly prone to longitudinal stent deformation (LSD) by adjunctive devices, instead of higher flexibility (17) . Indeed, LSD occurred in 0.56% of lesions in the current study. The For all variables, p < 0.05 by unadjusted analysis with stent fracture (SF). *Random intercepts in the model accounted for within-patient clustering of lesion characteristics.
CI ¼ confidence interval; OR ¼ odds ratio.
contributors of SF are not only flexibility, but also longitudinal strength because repetitive cardiac contraction exposes the stent to compression, torsion, elongation, bending, and shear stress. These findings were supported by the presence of type 3b SF (8) . Therefore, there is a little concern that type 3b SF might be likely to occur in PtCr-EES. In the present study, type 3b SF occurred in 27.8% of all SF lesions and was not more frequently observed in SF after
PtCr-EES implantation. Moreover, it is intriguing that hinge motion was not the largest contributor to SF after PtCr-EES implantation, and tortuosity was not found to be a predictor, which were completely different results from CoCr-EES and BES (7, 8) . These findings suggest that flexibility plays the pivotal role in the incidence of SF rather than longitudinal strength, and some SFs are unavoidable even in PtCr-EES because the stent is made of metal. Nevertheless, if a de novo lesion was treated with a single stent, including the 38-mm PtCr-EES, the incidence of SF after PtCr-EES implantation was very rare (0.48%) in the present study. Therefore, PtCr-EES may reduce the incidence of SF to the utmost limit of a metallic DES.
SF has been associated with a higher potential risk of ISR, TLR, and ST in the first-generation DES (4). We previously reported that SF after CoCr-EES and BES implantation was associated with major adverse cardiac events within 9 months after the index procedure, primarily because of clinically driven TLR or ST (8, 9) . Similarly, the present study showed a higher incidence of clinically driven TLR after PtCr-EES implantation in the SF group compared with the non-SF group. Therefore, SF remains an issue even in PtCr-EES. On the other hand, ST did not occur in the SF group in the present study. Although the current study has a potential for underestimation because of a relatively small study population and the very low incidence of SF, the lack of ST might be due to differences in stent platform between PtCr-EES and other DES. WHAT IS NEW? A total of 700 patients with 898 lesions undergoing PtCr-EES implantation were analyzed. SF was observed in 16 of 898 lesions (1.7%). Lesions with ISR at baseline or hinge motion, and total stent length were predictors of SF. The cumulative incidence of clinically driven TLR within 9 months after the index procedure was numerically higher in the SF group than that in the non-SF group (18.7% vs. 2.3%), whereas definite ST did not occur in the SF group.
WHAT IS NEXT? PtCr-EES may reduce the incidence of SF to the utmost limit of a metallic DES. 
